About Lipopolysaccharide-responsive and beige-like anchor protein
Lipopolysaccharide-responsive and beige-like anchor protein (LRBA) is a protein
from Homo sapiens identified by UniProt accession
P50851, 2863 residues long.
MolForge cross-references it against 0 known binders and
185 disease associations.
Target properties
| Protein name | Lipopolysaccharide-responsive and beige-like anchor protein |
|---|
| UniProt accession | P50851 |
|---|
| Gene | LRBA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 2863 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (185)
Diseases linked to this target (Open Targets).
- combined immunodeficiency due to LRBA deficiency · score 0.80
- common variable immunodeficiency · score 0.57
- colobomatous microphthalmia-rhizomelic dysplasia syndrome · score 0.52
- syndromic microphthalmia · score 0.52
- severe combined immunodeficiency due to CORO1A deficiency · score 0.41
- cholelithiasis · score 0.37
- neutrophil count · score 0.37
- leukocyte count · score 0.35
- alkaline phosphatase measurement · score 0.35
- vital capacity · score 0.34
3D Structure (9)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (2863 residues)
MASEDNRVPS PPPTGDDGGG GGREETPTEG GALSLKPGLP IRGIRMKFAV LTGLVEVGEV SNRDIVETVF NLLVGGQFDL EMNFIIQEGE SINCMVDLLE KCDITCQAEV WSMFTAILKK SIRNLQVCTE VGLVEKVLGK IEKVDNMIAD LLVDMLGVLA SYNLTVRELK LFFSKLQGDK GRWPPHAGKL LSVLKHMPQK YGPDAFFNFP GKSAAAIALP PIAKWPYQNG FTFHTWLRMD PVNNINVDKD KPYLYCFRTS KGLGYSAHFV GGCLIVTSIK SKGKGFQHCV KFDFKPQKWY MVTIVHIYNR WKNSELRCYV NGELASYGEI TWFVNTSDTF DKCFLGSSET ADANRVFCGQ MTAVYLFSEA LNAAQIFAIY QLGLGYKGTF KFKAESDLFL AEHHKLLLYD GKLSSAIAFT YNPRATDAQL CLESSPKDNP SIFVHSPHAL MLQDVKAVLT HSIQSAMHSI GGVQVLFPLF AQLDYRQYLS DEIDLTICST LLAFIMELLK NSIAMQEQML ACKGFLVIGY SLEKSSKSHV SRAVLELCLA FSKYLSNLQN GMPLLKQLCD HVLLNPAIWI HTPAKVQLML YTYLSTEFIG TVNIYNTIRR VGTVLLIMHT LKYYYWAVNP QDRSGITPKG LDGPRPNQKE MLSLRAFLLM FIKQLVMKDS GVKEDELQAI LNYLLTMHED DNLMDVLQLL VALMSEHPNS MIPAFDQRNG LRVIYKLLAS KSEGIRVQAL KAMGYFLKHL APKRKAEVML GHGLFSLLAE RLMLQTNLIT MTTYNVLFEI LIEQIGTQVI HKQHPDPDSS VKIQNPQILK VIATLLRNSP QCPESMEVRR AFLSDMIKLF NNSRENRRSL LQCSVWQEWM LSLCYFNPKN SDEQKITEMV YAIFRILLYH AVKYEWGGWR VWVDTLSITH SKVTFEIHKE NLANIFREQQ GKVDEEIGLC SSTSVQAASG IRRDINVSVG SQQPDTKDSP VCPHFTTNGN ENSSIEKTSS LESASNIELQ TTNTSYEEMK AEQENQELPD EGTLEETLTN ETRNADDLEV SSDIIEAVAI SSNSFITTGK DSMTVSEVTA SISSPSEEDA SEMPEFLDKS IVEEEEDDDY VELKVEGSPT EEANLPTELQ DNSLSPAASE AGEKLDMFGN DDKLIFQEGK PVTEKQTDTE TQDSKDSGIQ TMTASGSSAM SPETTVSQIA VESDLGQMLE EGKKATNLTR ETKLINDCHG SVSEASSEQK IAKLDVSNVA TDTERLELKA SPNVEAPQPH RHVLEISRQH EQPGQGIAPD AVNGQRRDSR STVFRIPEFN WSQMHQRLLT DLLFSIETDI QMWRSHSTKT VMDFVNSSDN VIFVHNTIHL ISQVMDNMVM ACGGILPLLS AATSATHELE NIEPTQGLSI EASVTFLQRL ISLVDVLIFA SSLGFTEIEA EKSMSSGGIL RQCLRLVCAV AVRNCLECQQ HSQLKTRGDK ALKPMHSLIP LGKSAAKSPV DIVTGGISPV RDLDRLLQDM DINRLRAVVF RDIEDSKQAQ FLALAVVYFI SVLMVSKYRD ILEPQNERHS QSCTETGSEN ENVSLSEITP AAFSTLTTAS VEESESTSSA RRRDSGIGEE TATGLGSHVE VTPHTAPPGV SAGPDAISEV LSTLSLEVNK SPETKNDRGN DLDTKATPSV SVSKNVNVKD ILRSLVNIPA DGVTVDPALL PPACLGALGD LSVEQPVQFR SFDRSVIVAA KKSAVSPSTF NTSIPTNAVS VVSSVDSAQA SDMGGESPGS RSSNAKLPSV PTVDSVSQDP VSNMSITERL EHALEKAAPL LREIFVDFAP FLSRTLLGSH GQELLIEGTS LVCMKSSSSV VELVMLLCSQ EWQNSIQKNA GLAFIELVNE GRLLSQTMKD HLVRVANEAE FILSRQRAED IHRHAEFESL CAQYSADKRE DEKMCDHLIR AAKYRDHVTA TQLIQKIINI LTDKHGAWGN SAVSRPLEFW RLDYWEDDLR RRRRFVRNPL GSTHPEATLK TAVEHVCIFK LRENSKATDE DILAKGKQSI RSQALGNQNS ENEILLEGDD DTLSSVDEKD LENLAGPVSL STPAQLVAPS VVVKGTLSVT SSELYFEVDE EDPNFKKIDP KILAYTEGLH GKWLFTEIRS IFSRRYLLQN TALEIFMANR VAVMFNFPDP ATVKKVVNYL PRVGVGTSFG LPQTRRISLA SPRQLFKASN MTQRWQHREI SNFEYLMFLN TIAGRSYNDL NQYPVFPWVI TNYESEELDL TLPTNFRDLS KPIGALNPKR AAFFAERYES WEDDQVPKFH YGTHYSTASF VLAWLLRIEP FTTYFLNLQG GKFDHADRTF SSISRAWRNS QRDTSDIKEL IPEFYYLPEM FVNFNNYNLG VMDDGTVVSD VELPPWAKTS EEFVHINRLA LESEFVSCQL HQWIDLIFGY KQQGPEAVRA LNVFYYLTYE GAVNLNSITD PVLREAVEAQ IRSFGQTPSQ LLIEPHPPRG SAMQVSPLMF TDKAQQDVIM VLKFPSNSPV THVAANTQPG LATPAVITVT ANRLFAVNKW HNLPAHQGAV QDQPYQLPVE IDPLIASNTG MHRRQITDLL DQSIQVHSQC FVITSDNRYI LVCGFWDKSF RVYSTDTGRL IQVVFGHWDV VTCLARSESY IGGNCYILSG SRDATLLLWY WNGKCSGIGD NPGSETAAPR AILTGHDYEV TCAAVCAELG LVLSGSQEGP CLIHSMNGDL LRTLEGPENC LKPKLIQASR EGHCVIFYEN GLFCTFSVNG KLQATMETDD NIRAIQLSRD GQYLLTGGDR GVVVVRQVSD LKQLFAYPGC DAGIRAMALS YDQRCIISGM ASGSIVLFYN DFNRWHHEYQ TRY
Explore Lipopolysaccharide-responsive and beige-like anchor protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets